Pfizer announces the 2016 U.S. ASPIRE Hemophilia Research Awards Program


The 2016 U.S. Advancing Science through Pfizer: Investigator Research Exchange (ASPIRE) Hemophilia Research Awards Program is a competitive grants program that reflects the commitment of Pfizer Hemophilia to support ongoing basic science and clinical investigation in hemophilia A and B.

Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for hemophilia A and hemophilia B and their related comorbidities. In an era of increased competition for research funding, the 2016 U.S. ASPIRE Hemophilia Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of hemophilia A and B.


Areas of Research Focus

Pfizer will consider proposals for research projects which address one of the following areas in hemophilia A and/or hemophilia B.  Applications comprising laboratory investigation or clinical research will be considered.

Application and Selection Process

The 2016 U.S. ASPIRE Program is open to U.S. investigators. Review of grant proposals will be performed by an independent, external panel of experts. Project duration should be 1 or 2 years and the annual approximate award will be up to $125,000/year, inclusive of overhead costs (capped at 28%).

Proposals must be received by April 25, 2016.